Bookmark and Share

1980s Publications

A.I. FADEN and J.W. Holaday. Naloxone treatment of endotoxin shock: Stereo-specificity of physiologic and pharmacologic effects in the rat. J Pharmacol Exp Ther 212: 441-447, 1980.

A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Endorphin-parasympathetic interactions in spinal shock. J Auton Nerv Syst 2: 295-304, 1980.

A.I. FADEN and T.P. Jacobs. Cardiac contractility and the spinal sympathetic neuron. Neurol Res 1: 227-237, 1980.

J.W. Holaday and A.I. FADEN. Naloxone acts at central opiate receptors to reverse hypotension, hypothermia, and hypoventilation in spinal shock. Brain Res 189: 295-299, 1980.

D.G. Reynolds, N.J. Gurll, T. Vargish, R. Lechner, A.I. FADEN, and J.W. Holaday. Blockade of opiate receptors with Naloxone improves survival and cardiac performance in canine endotoxic shock. Circ Shock 7: 39-48, 1980.

T. Vargish, D.G. Reynolds, N.J. Gurll, R.B. Lechner, J.W. Holaday, and A.I. FADEN. Naloxone reversal of hypovolemic shock in dogs. Circ Shock 7: 31-38, 1980.

A.I. FADEN and J.W. Holaday. Experimental endotoxin shock: The pathophysiologic function of endorphins and treatment with opiate antagonists. J Infect Dis (Review) 142: 229-238, 1980.

A.I. FADEN, T.P. Jacobs, G. Feuerstein, and J.W. Holaday. Dopamine partially mediates the cardiovascular effects of Naloxone after spinal injury. Brain Res 213: 415-421, 1981.

A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Opiate antagonist improves neurologic recovery after spinal injury. Science 211: 493-494, 1981.

A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Eng J Med 305:1063-1067, 1981.

A.I. FADEN, T.P. Jacobs, E.H. Mougey, and J.W. Holaday. Endorphins in experimental spinal injury: Therapeutic effect of Naloxone. Ann Neurol 10: 326-332, 1981.

A.I. FADEN and E. Mendoza. Peripheral sensorimotor neuropathy associated with chronic obstructive pulmonary disease: A prospective clinical and electrophysiologic study. Arch Neurol 38: 639-642, 1981.

R. Faden, C. Becker, C. Lewis, J.B. Freeman, and A.I. FADEN. Disclosure of information to patients in medical care. Med Care 19: 718-733, 1981.

R. Faden, C. Lewis, C. Becker, A.I. FADEN, and J.B. Freeman. Disclosure standards and informed consent. J Health Politics Policy Law 6: 255-284, 1981.

J.W. Holaday, R. D'Amato, and A.I. FADEN. Thyrotropin-releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. Science 213: 216-218, 1981.

J.W. Holaday, M. O'Hara, and A.I. FADEN. Hypophysectomy alters cardiorespiratory variables: Central effects of pituitary endorphins in shock. Am J Physiol 241: H479-H485, 1981.

J.W. Holaday, B.A. Ruvio, and A.I. FADEN. Thyrotropin-releasing hormone improves blood pressure and survival in endotoxic shock. Eur J Pharmacol 4: 101-105, 1981.

A.I. FADEN, P. Chan, and E. Mendoza. Progressive isolated segmental anhidrosis. Arch Neurol 39: 172-175, 1982.

A.I. FADEN, J.M. Hallenbeck, and C.Q. Brown. Treatment of experimental stroke: Comparison of Naloxone and thyrotropin releasing hormone. Neurology 32: 1083-1087, 1982.

A.I. FADEN, T.P. Jacobs, and J.W. Holaday. Comparison of early and late Naloxone treatment in experimental spinal injury. Neurology 32: 677-681, 1982.

G.Z. Feuerstein and A.I. FADEN. Differential cardiovascular effects of µ, d, and k opiate agonists at discrete hypothalamic sites in the anesthetized rat. Life Sci 31: 2197-2200, 1982.

A.H. Hassen, G.Z. Feuerstein, and A.I. FADEN. Cardiovascular responses to opioid agonists injected into the nucleus tractus solitarius of anesthetized cats. Life Sci 31: 2193-2196, 1982.

A.H. Hassen, G.Z. Feuerstein, and A.I. FADEN. µ receptors and opioid cardiovascular effects in the NTS of the rat. Peptides 3: 1031-1037, 1982.

A.H. Hassen, G.Z. Feuerstein, A. Pfeiffer, and A.I. FADEN. Delta versus mu receptors receptors: Cardiovascular and respiratory effects of opiate agonists micro-injected into nucleus tractus solitarius of cats. Reg Peptides 4: 299-309, 1982.

C.J. Molineaux, G.Z. Feuerstein, A.I. FADEN, and B.M. Cox. Distribution of immunoreactive dynorphin in discrete brain nuclei: Comparison with vasopressin. Neurosci Lett 3: 170-184, 1982.

Pfeiffer, G.Z. Feuerstein, A.I. FADEN, and I.J. Kopin. Evidence for an involvement of µ- but not ∆- or k-opiate receptors in sympathetically and parasympathetically mediated cardiovascular responses to opiates upon intrahypothalamic microinjection. Life Sci 31: 1279-1282, 1982.

A.I. FADEN and G. Feuerstein. Hypothalamic regulation of the cardiovascular and respiratory systems: Role of specific opiate receptors. Br J Pharmacol 79: 997-1002, 1983.

A.I. FADEN and T.P. Jacobs. Dynorphin induces partially reversible paraplegia in the rat. Eur J Pharmacol 91: 321-324, 1983.

A.I. FADEN, T.P. Jacobs, G.P. Smith, G. Green, and J. Zivin. Neuropeptides in spinal cord injury: Comparative experimental models. Peptides 4: 631-634, 1983.

A.I. FADEN, T.P. Jacobs, M.T. Smith, and J.W. Holaday. Comparison of thyrotropin releasing hormone (TRH), Naloxone and dexamethasone treatments in experimental spinal injury. Neurology 33: 673-678, 1983.

A.I. FADEN, T.P. Jacobs, and J.A. Zivin. Comparison of Naloxone and a d-selective antagonist in experimental spinal stroke. Life Sci 33 (Suppl 1): 707-710, 1983.

G. Feuerstein and A.I. FADEN. Central autonomic effects of dermorphin in conscious rats. J Pharmacol Exp Ther 226:151-156, 1983.

Feuerstein and A.I. FADEN. Dermorphin: Cardiovascular and sympathetic modulation in the anteroventral hypothalamus of conscious rats. Life Sci (Suppl 1) 33: 731-734, 1983.

G. Feuerstein, A.H. Hassen, and A.I. FADEN. TRH: Cardiovascular and sympathetic modulation in brain nuclei of the rat. Peptides 4: 617-620, 1983.

G. Feuerstein, C. Molineaux, J. Rosenberger, A.I. FADEN, and B. Cox. Dynorphin and leuenkephalin in brain nuclei and pituitary of WKY and SHR rats. Peptides 4: 225-229, 1983.

G. Feuerstein, R. Zerbe, and A.I. FADEN. Opiate receptors and cardiovascular control in conscious SHR and WKY rats. Hypertension 5: 663-671, 1983.

G. Feuerstein, Z. Zukowska-Grojec, M. Bayorh, I.J. Kopin, and A.I. FADEN. Leukotriene D4-induced hypotension is reversed by thyrotropin-releasing hormone. Prostaglandins 26: 711-724, 1983.

S.C. Gilman, M.J. Ackerman, J.M. Hallenbeck, and A.I. FADEN. Failure of Naloxone or ß-endorphin to affect pressure-induced tremor in the guinea pig. Undersea Biomed Res 10: 89-93, 1983.

J.M. Hallenbeck, T.P. Jacobs, and A.I. FADEN. Combined PGI2, indomethacin and heparin improves neurological recovery after spinal trauma in cats. J Neurosurg 58: 749-754, 1983.

A.H. Hassen, G. Feuerstein, and A.I. FADEN. Differential cardiovascular effects mediated by µ and k opiate receptors in hindbrain nuclei. Peptides 4: 621-625, 1983.

J.W. Holaday, R.J. D’Amato, B.A. Ruvio, G. Feuerstein, and A.I. FADEN. Adrenalectomy blocks pressor responses to Naloxone in endotoxic shock: Evidence for sympathomedullary involvement. Circ Shock 11: 201-210, 1983.

J.W. Holaday and A.I. FADEN. Thyrotropin-releasing hormone: Autonomic effects upon cardiorespiratory function in endotoxic shock. Reg Peptides 7: 125, 1983.

J.W. Holaday, G.W. Pasternak, R.J. D’Amato, B.A. Ruvio, and A.I. FADEN. Naloxone lacks therapeutic effects in endotoxic shock yet blocks the effects of nNaloxone. Eur J Pharmacol 89: 293-296, 1983.

J.W. Holaday, G.W. Pasternak, and A.I. FADEN. Naloxazone pretreatment modifies cardiorespiratory, temperature and behavioral effects of morphine. Neurosci Lett 37: 199-204, 1983.

W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Alteration of leukotriene D4 hypotension by thyrotropin-releasing hormone. Nature 302: 8Z-824, 1983.

W.E. Lux, Jr., G.Z. Feuerstein, and A.I. FADEN. Thyrotropin-releasing hormone reverses the hypotension and bradycardia produced by leukotriene D4 in unanesthetized guinea pigs. Prostag Leukot Med 10: 301-308, 1983.

W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Thyrotropin-releasing hormone reverses experimental anaphylactic shock through non-endorphin-related mechanisms. Eur J Pharmacol 90: 301-302, 1983.

Pfeiffer, G. Feuerstein, I.J. Kopin, and A.I. FADEN. Cardiovascular and respiratory effects of µ-, Δ- and -opiate agonists microinjected into the anterior hypothalamic brain area of awake rats. J Pharmacol Exp Ther 225: 735﷓741, 1983.

Pfeiffer, G. Feuerstein, R.L. Zerbe, A.I. FADEN, and I.J. Kopin. µ receptors mediate opioid cardiovascular effects at anterior hypothalamic sites through sympathoadrenomedullary and parasympathetic pathways. Endocrinology 113: 929-938, 1983.

R.L. Zerbe, S. Kirtland, A.I. FADEN, and G. Feuerstein. Central cardiovascular effects of mammalian neurohypophyseal peptides in conscious rats. Peptides 4: 627-630, 1983.

A.I. FADEN. Neuropeptides and stroke: Current status and potential application. Stroke (Review) 14: 169-172, 1983.

A.I. FADEN. Opiate antagonists in the treatment of stroke. Curr Concepts Cerebrovasc Dis (Review) 18: 27-31, 1983.

A.I. FADEN. Recent pharmacological advances in experimental spinal injury: Theoretical and methodological considerations. Trends Neurosci (Review) 6: 375-377, 1983.

A.I. FADEN. Opiate antagonists and thyrotropin-releasing hormone: I. Potential role in the treatment of shock. JAMA (Review) 252: 1177-1180, 1984.

A.I. FADEN. Opiate antagonists and thyrotropin-releasing hormone: II. Potential role in the treatment of central nervous system injury. JAMA (Review) 252: 1452-1454, 1984.

A.I. FADEN. Endogenous opioids: Physiologic and pathophysiologic actions. J Am Osteopath Assoc (Review) 84 (Suppl. 1): 129-134, 1984.

A.I. FADEN and T.P. Jacobs. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action. Br J Pharmacol 81: 271ï·“276, 1984.

A.I. FADEN, T.P. Jacobs, D.H. Patrick, and M.T. Smith. Megadose corticosteroid therapy following experimental traumatic spinal injury. J Neurosurg 60: 712-716, 1984.

A.I. FADEN, T.P. Jacobs, and M.T. Smith. Evaluation of the calcium channel antagonist nimodipine in experimental spinal cord ischemia. J Neurosurg 60: 796-799, 1984.

G. Feuerstein, A.I. FADEN, and S.A. Krumins. Alteration in opiate receptor binding after hemorrhagic shock. Eur J Pharmacol 100: 245-246, 1984.

G. Feuerstein, C. Helke, and A.I. FADEN. Differential changes in substance P and somatostatin in brain nuclei of rats exposed to hemorrhagic shock. Brain Res 300: 305-310, 1984.

G. Feuerstein, A.K. Johnson, R.L. Zerbe, R. Davis-Kramer, and A.I. FADEN. Anteroventral hypothalamus and hemorrhagic shock: Cardiovascular and neuroendocrine responses. Am J Physiol 246:R551-R557, 1984.

G. Feuerstein, R.L. Zerbe, and A.I. FADEN. Central cardiovascular effects of vasotocin, oxytocin and vasopressin in conscious rats. J Pharmacol Exp Ther 228: 348-353, 1984.A.H. Hassen, G. Feuerstein, and A.I. FADEN. Κ opioid receptors modulate cardiorespiratory function in hindbrain nuclei of rat. J Neurosci 4: 2213-2221, 1984.

A.H. Hassen, G. Feuerstein, and A.I. FADEN. Selective cardiorespiratory effects mediated by µ-opioid receptors in the nucleus ambiguous. Neuropharmacol 23: 407-415, 1984.

Pfeiffer, D. Pfeiffer, G. Feuerstein, A.I. FADEN and I.J. Kopin. An increase in opiate receptor-sites is associated with enhanced cardiovascular depressant, but not respiratory depressant action of morphine. Brain Res 296: 305-311, 1984.

A.I. FADEN, T.P. Jacobs, and M.T. Smith. Thyrotropin-releasing hormone in experimental spinal injury: Dose response and late treatment. Neurology 34: 1280-1284, 1984.

A.I. FADEN, T.P. Jacobs, M.T. Smith, and J.A. Zivin. Naloxone in experimental spinal cord ischemia: Dose response studies. Eur J Pharmacol 103: 115-120, 1984.

W.E. Lux, Jr., G. Feuerstein, and A.I. FADEN. Effects of thyrotropin-releasing hormone (TRH) on lipoxygenase-induced hypotension in the unanesthetized guinea pig. Pharm Res 3: 135-137, 1984.

G. Feuerstein, W.E. Lux, Jr., F. Snyder, D. Ezra, and A.I. FADEN. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. Circ Shock 13: 255-260, 1984.

G. Feuerstein, D. Lozovsky, L.A. Cohen, V.M. Labroo, K.L. Kirk, I.J. Kopin, and A.I. FADEN. Differential effect of fluorinated analogs of TRH on the cardiovascular system and prolactin release. Neuropeptides 4: 303-310, 1984.

G.Z. Feuerstein, W.E. Lux, Jr., D. Ezra, and A.I. FADEN. Reversal of leukotriene hypotension by thyrotropin releasing hormone. Neurosci Res 2: 121-124, 1984.

G. Feuerstein, C.J. Molineaux, J.G. Rosenberger, R.L. Zerbe, B.M. Cox, and A.I. FADEN. Effect of hemorrhage on vasopressin, dynorphin A and leu5-enkephalin in the hypothalamopituitary system of the rat. Clin Exp Hyperten A6: 1973-1976, 1984.

G. Feuerstein and A.I. FADEN. Cardiovascular effects of dynorphin A-(1-8), dynorphin A-(1-3) and dynorphin A-(1-17) microinjected into the preoptic medialis nucleus of the rat. Neuropeptides 5: 295-298, 1984.

B.M. Cox, C.J. Molineaux, T.P. Jacobs, J.G. Rosenberger, and A.I. FADEN. Effects of traumatic injury on dynorphin immunoreactivity in spinal cord. Neuropeptides 5: 571-574, 1985.

A.I. FADEN, S. Knoblach, C. Mays, and T.P. Jacobs. Motor dysfunction after spinal cord injury is mediated by opiate receptors. Peptides 6 (Suppl. 1): 15ï·“17, 1985.

G. Feuerstein, E. Powell, and A.I. FADEN. Central effects of µ-, ∆- and k﷓receptor agonists in hemorrhagic shock. Peptides 6 (Suppl. 1) 13, 1985.

A.I. FADEN, C.J. Molineaux, J.G. Rosenberger, T.P. Jacobs, and B.M. Cox. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Reg Peptides 11: 35-41, 1985.

G. Feuerstein, W.E. Lux, Jr., D. Ezra, E.C. Hayes, F. Snyder, and A.I. FADEN. Thyrotropin-releasing hormone blocks the hypotensive effects of platelet activating factor in the unanesthetized guinea pig. J Cardiovasc Pharmacol 7: 335-340, 1985.

N. Zamir, D. Zamir, L. Eiden, M. Palkovits, M.J. Brownstein, R. Eskay, E. Weber, A.I. FADEN, and G. Feuerstein. Methionine- and leucine-enkephalin in rat neurohypophysis: Different responses to osmotic stimuli and T-2 toxin. Science 228: 604-608, 1985.

Feuerstein, D. Goldstein, P.W. Ramwell, R.L. Zerbe, W. Lux, Jr., A.I. FADEN, and M.A. Bayorh. Cardiorespiratory, sympathetic and biochemical responses to T-2 toxin in the guinea pig and rat. J Pharmacol Exp Ther 232: 786ï·“794, 1985.

S.A. Krumins, A.I. FADEN, and G. Feuerstein. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 127: 120-128, 1985.

M.A. Bayorh, A.I. FADEN, and G. Feuerstein. Differential hemodynamic effects of leukotriene D4 in anesthetized rats: Evaluation by directional pulsed Doppler technique. Prostag Leukot Med 17: 229-241, 1985.

A.I. FADEN and T.P. Jacobs. Opiate antagonist WIN44,441-3 stereospecifically improves neurologic recovery after ischemic spinal injury. Neurology 35: 1311ï·“1315, 1985.

A.I. FADEN and T.P. Jacobs. Effect of TRH analogs on neurologic recovery after experimental spinal trauma. Neurology 35:1331-1334, 1985.

A.I. FADEN, C.J. Molineaux, J.G. Rosenberger, T.P. Jacobs, and B.M. Cox. Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury. Ann Neurol 17: 386-390, 1985.

A.I. FADEN, T.P. Jacobs, and C.J. Helke. Changes in substance P and somatostatin in the spinal cord after traumatic spinal injury in the rat. Neuropeptides 6: 215-225, 1985.

G. Feuerstein, M.A. Bayorh, R.E. Stull, D.S. Goldstein, R.L. Zerbe, P.W. Ramwell, and A.I. FADEN. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats. Circ Shock 17: 223-232, 1985.

J. Eimerl, M.A. Bayorh, Z. Zukowska-Grojec, A.I. FADEN, D. Ezra, and G. Feuerstein. Substance K: Vascular and cardiac effects in rat and pig. Peptides 6 (Suppl. 2): 149-153, 1985.

A.I. FADEN. New pharmacological approaches to spinal cord injury: Opiate antagonists and thyrotropin-releasing hormone. CNS Trauma (Review) 2: 5-8, 1985.

T. Hokfelt, L. Skirboll, B. Everett, B. Meister, M. Brownstein, T. Jacobs, A. FADEN, S. Kaga, M. Goldstein, R. Markstein, G. Dockray, and J. Rehfeld. Distribution of cholecystokinin-like immunoreactivity in the nervous system with special reference to coexistence with classical neurotransmitters and other neuropeptides. Ann NY Acad Sci 448: 255-274, 1985.

T.K. McIntosh and A.I. FADEN. Thyrotropin-releasing hormone and circulatory shock. Circ Shock (Review) 18: 241-258, 1986.

T.K. McIntosh and A.I. FADEN. Opiate antagonists in traumatic shock. Ann Emerg Med (Review) 15: 1462-1465, 1986.

S.A. Krumins and A.I. FADEN. Traumatic injury alters opiate receptor binding in rat spinal cord. Ann Neurol 19: 498-501, 1986.

A.I. FADEN, N.S. Pilotte, and D.R. Burt. Experimental spinal cord injury: Effects of trauma or ischemia on TRH and muscarinic receptors. Neurology 36: 723-736, 1986.

A.I. FADEN, T.G. Hill, and M. Kubek. Changes in TRH immunoreactivity in spinal cord after experimental spinal injury. Neuropeptides 7:11-18, 1986.

A.I. FADEN. Neuropeptides and central nervous system injury: Clinical implications. Arch Neurol 43: 501-504, 1986.

A.I. FADEN, P.H. Chan, and S. Longar. Alterations in lipid metabolism, (Na+,K+)-ATPase activity, and tissue water content of spinal cord following experimental traumatic injury. J Neurochem 48: 1809-1816, 1987.

R. Vink, T.K. McIntosh, and A.I. FADEN. Metabolic changes following central nervous system trauma as determined by in vivo magnetic resonance spectroscopy. US Med 23: 20, 1987.

R. Vink, T.K. McIntosh, M.W. Weiner, and A.I. FADEN. Effects of traumatic brain injury on cerebral high-energy phosphates and pH: A 31P magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 7: 563-571, 1987.

T.K. McIntosh, A.I. FADEN, M.R. Bendall, and R. Vink. Traumatic brain injury in the rat: Alteration in brain lactate and pH as characterized by 1H and 31P NMR. J Neurochem 49: 1530-1540, 1987.

M. Lemke, P. Demediuk, T.K. McIntosh, R. Vink, and A.I. FADEN. Alterations in tissue Mg2+, Na+ and spinal cord edema following impact trauma in rats. Biochem Biophys Res Commun 147: 1170-1175, 1987.

T.K. McIntosh, R.L. Hayes, D.S. DeWitt, V. Agura, and A.I. FADEN. Endogenous opioids may mediate secondary damage after experimental brain injury. Am J Physiol 253: E565-E574, 1987.

R. Vink, S.M. Knoblach, and A.I. FADEN. 31P magnetic resonance spectroscopy of traumatic spinal cord injury. Magn Res Med 5: 390-394, 1987.

T.K. McIntosh, L. Noble, B. Andrews, and A.I. FADEN. Traumatic brain injury in the rat: Characterization of a midline fluid percussion model. CNS Trauma 4: 119-134, 1987.

R. Vink, T.K. Mclntosh, P. Demediuk, and A.I. FADEN. Decrease in total and free magnesium concentration following traumatic brain injury in rats. Biochem Biophys Res Comm 149: 594-599, 1987.

A.I. FADEN, A.E. Takemori, P.S. Portoghese. k-Selective opiate antagonist norbinaltorphimine improves outcome after traumatic spinal cord injury in rats. CNS Trauma 4: 227-237, 1987.

T.K. McIntosh, V.A. Head, and A.I. FADEN. Alterations in regional concentrations of endogenous opioids following traumatic brain injury in the cat. Brain Res 425: 225-233, 1987.

A.I. FADEN. Pharmacotherapy in spinal cord injury: A critical review of recent developments. Clin Neuropharm (Review) 10:193-204, 1987.

A.I. FADEN. Opiate-receptor antagonists, thyrotropin-releasing hormone (TRH) and TRH analogs in the treatment of spinal cord injury. CNS Trauma (Review) 4: 217-226, 1987.

R. Vink, T.K. McIntosh, S. Fernyak, M.W. Weiner, and A.I. FADEN. Proton and phosphorous NMRI studies of traumatic brain injury in rats. Ann NY Acad Sci 508: 497-500, 1988.

R. Vink, T.K. McIntosh, P. Demediuk, M. Weiner, A.I. FADEN. Decline in intracellular free Mg2+ is associated with irreversible tissue injury after brain trauma. J Biol Chem 263: 757-761, 1988.

A.I. FADEN, I. Sacksen, and L.J. Noble. Structure-activity relationships of TRH analogs in experimental spinal cord injury. Brain Res 448: 287ï·“293, 1988.

A.I. FADEN, A. Gannon, and A.I. Basbaum. Use of serotonin immunocytochemistry as a marker of injury severity after experimental spinal trauma in rats. Brain Res 450: 94-100, 1988.

B.T. Andrews, P.R. Weinstein, and A.I. FADEN. Computerized cortical surface electroencephalography after temporary middle cerebral artery occlusion in rabbits. Neurosurgery 22: 681-686, 1988.

A.I. FADEN, M. Lemke, R.P. Simon, and L.J. Noble. N-methyl-D-aspartate antagonist MK801 improves outcome following traumatic spinal cord injury in rats: Behavioral, anatomic and neurochemical studies. J Neurotrauma 5: 33-45, 1988.

A.I. FADEN, L. Sacksen, and L.J. Noble. Opiate-receptor antagonist Nalmefene improves neurological recovery after traumatic spinal cord injury in rats. J Pharmacol Exp Ther 245: 742-748, 1988.

A.I. FADEN and R.P. Simon. A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol 23: 623-626, 1988.

R. Vink, T.K. McIntosh, I. Yamakami, and A.I. FADEN. 31P NMR characterization of graded traumatic brain injury in rats. Magn Res Med 6: 37-48, 1988.

T.K. McIntosh, R. Vink, and A.I. FADEN. An analogue of thyrotropin-releasing hormone improves outcome after brain injury: 31P NMR studies. Am J Physiol 254: R785-R792, 1988.

P. Demediuk and A.I. FADEN. Traumatic spinal cord injury in rats causes increases in tissue thromboxane but not peptidoleukotrienes. J Neurosci 20: 115-121, 1988.

A.I. FADEN, M. Lemke, and P. Demediuk. Effects of BW755C, a mixed cyclo-oxygenase-lipoxygenase inhibitor, following traumatic spinal cord injury in rats. Brain Res 463: 63-68, 1988.

R. Vink, T.K. McIntosh, and A.I. FADEN. Non-edited lH NMR lactate/n-acetyl aspartate ratios for in vivo determination of lactate concentration in brain. Magn Res Med 7: 95-99, 1988.

R. Vink, T.K. McIntosh, and A.I. FADEN. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. Brain Res 460: 184-188, 1988.

T.K. McIntosh, A.I. FADEN, I. Yamakami, and R. Vink. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and behavioral studies. J Neurotrauma 5: 17-31, 1988.

B.T. Andrews, T.K. McIntosh, M.G. Gonzalez, P. Weinstein, and A.I. FADEN. Levels of endogenous opioids and effects of an opiate antagonist during regional cerebral ischemia in rats. J Pharmacol Exp Ther 247: 1248ï·“1254, 1988.

R. Vink, A.I. FADEN, and T.K. McIntosh. Changes in cellular bioenergetic state following graded traumatic brain injury in rats: Determination by 31Phosphorus magnetic resonance spectroscopy. J Neurotrauma 5: 315ï·“330, 1988.

R. Vink, L.J. Noble, S.M. Knoblach, M.R. Bendall, and A.I. FADEN. Metabolic changes in rabbit spinal cord after trauma: Magnetic resonance spectroscopy studies. Ann Neurol 25: 26-31, 1989.

A.I. FADEN. TRH analog YM-14673 improves outcome following traumatic brain and spinal cord injury in rats: Dose response studies. Brain Res 486: 228-235, 1989.

A.I. FADEN, P. Demediuk, S. Panter, and R. Vink. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244: 798ï·“800, 1989.

T.K. McIntosh, R. Vink, I. Yamakami, and A.I. FADEN. Magnesium protects against neurological deficit after brain injury. Brain Res 482: 252-260, 1989.

P. Demediuk, M.P. Daly, and A.I. FADEN. Effect of impact trauma on neurotransmitter and non-neurotransmitter amino acids in rat spinal cord. J Neurochem 52: 1529-1536, 1989.

T.K. McIntosh, R. Vink, L. Noble, I. Yamakami, S. Fernyak, and A.I. FADEN. Traumatic brain injury in the rat: Characterization of a lateral fluid-percussion model. Neuroscience 28: 233-244, 1989.

R. Vink, S. Yum, M. Lemke, P. Demediuk, and A.I. FADEN. Traumatic spinal cord injury in rabbits decreases intracellular free magnesium concentration as measured by 31P MRS. Brain Res 490: 144-147, 1989.